Virtual Library
Start Your Search
C. Zhang
Author of
-
+
Best abstracts selected from submissions 7 (ID 5)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
-
+
OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study (ID 211)
16:20 - 17:00 | Author(s): C. Zhang
- Abstract
Background:
NSCLC patients with 21 L858R mutation are less responsive to EGFR TKI treatment. This study aims to determine if high-dose icotinib can improve tumor response and progression-free survival (PFS) in this patient population.
Method:
In this randomized, open-label, multicenter phase II trial (INCREASE), patients with treatment-na